NEW YORK – Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry Genetics, Ares announced on Tuesday.

纽约——Tempus AI 已从另类投资管理公司 Ares Management 获得额外 3 亿美元的增量债务融资，这笔资金旨在支持该公司最近对 Ambry Genetics 的收购，Ares 于周二宣布。

Ares Credit funds have provided Tempus with a total debt package of about $560 million, including $260 million of capital in 2022 and 2023.

阿瑞斯信贷基金为腾普斯提供了总计约 5.6 亿美元的债务融资方案，其中包括 2022 年和 2023 年的 2.6 亿美元资本。

'Over the last two years, we’ve been impressed by the Tempus team's execution of its growth strategy and complementary acquisition of Ambry, and we look forward to further supporting their efforts in AI-enabled solutions that help advancements in medicine,' Douglas Dieter, partner in the Ares Credit Group, said in a statement..

“在过去的两年里，Tempus 团队在执行其增长战略和互补收购 Ambry 方面给我们留下了深刻印象，我们期待进一步支持他们在人工智能解决方案方面的努力，这些解决方案有助于医学的进步，”Ares Credit Group 合伙人 Douglas Dieter 在一份声明中表示。

Tempus announced

Tempus 宣布

its

它的

acquisition

收购

of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the

安布里遗传学公司以3.75亿美元现金和2.25亿美元股票在11月收盘时出售。

deal

交易

closed

关闭

earlier this month. Ambry will continue to operate as a wholly owned subsidiary of Tempus under its current leadership team. Before the acquisition, Ambry served as Tempus' largest reference laboratory for hereditary cancer screening, and the companies had entered a

本月初。Ambry将继续作为Tempus的全资子公司在其现任领导团队下运营。在收购之前，Ambry曾是Tempus在遗传性癌症筛查方面最大的参考实验室，两家公司已经达成了一项

strategic collaboration

战略协作

to provide a combined comprehensive germline and somatic testing service.

提供综合的生殖细胞和体细胞检测服务。